Semaglutide
:Type 2 diabetes
:Phase 2
Novo Nordisk is developing a longer-acting human GLP-1 analogue intended for once-weekly administration. Semaglutide is based on Novo Nordisk's protein acylation technology.
- Company announcements
- No company announcements matching the search criteria
- Press releases
- No press releases matching the search criteria
- Scientific abstracts
No scientific abstracts matching the search criteria
